Intervention with oral LPCN 1148 improves sarcopenia and hepatic encephalopathy (HE) in patients with cirrhosis: a 52-week phase 2 randomized clinical trial

被引：0

作者：

Bruno, Benjamin ^{[1
]}

Weavil, Josh ^{[1
]}

Ogle, Jonathan ^{[1
]}

Chidambaram, Nachaippan ^{[1
]}

Carey, Elizabeth ^{[2
,3
]}

Danford, Christopher ^{[4
]}

Fricker, Zachary ^{[5
]}

Galati, Joseph ^{[6
]}

Lee, William M. ^{[7
]}

Mantry, Parvez ^{[8
]}

Shetty, Kirti ^{[9
]}

DelConte, Anthony ^{[10
]}

Patel, Mahesh ^{[1
]}

Sanyal, Arun J. ^{[11
]}

Lai, Jennifer ^{[12
]}

机构：

[1] Lipocine Inc, Salt Lake City, UT USA

[2] Mayo Clin Arizona, Div Hepatol, Phoenix, AZ USA

[3] Mayo Clin Arizona, Div Gastroenterol, Phoenix, AZ USA

[4] Intermountain Med Ctr, Transplant Serv, Murray, KY USA

[5] Beth Israel Deaconess Med Ctr, Dept Gastroenterol Hepatol & Nutr, Boston, MA USA

[6] Liver Specialists Texas, Houston, TX USA

[7] Univ Texas SouthWestern Med Ctr, Div Digest & Liver Dis, Dallas, TX USA

[8] Methodist Dallas Med Ctr, Liver Inst, Res & Hepatobiliary Tumor Program, Dallas, TX USA

[9] Univ Maryland, Sch Med, Div Gastroenterol & Hepatol, Baltimore, MD USA

[10] St Josephs Univ, Dept Food Pharma & Healthcare, Philadelphia, PA USA

[11] Virginia Commonwealth Univ, Stravitz Sanyal Inst Liver Dis & Metab Hlth, Richmond, VA USA

[12] Univ Calif San Francisco, Div Gastroenterol & Hepatol, San Francisco, CA USA

来源：

JOURNAL OF HEPATOLOGY | 2024年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

LBO-005

引用

页码：S10 / S11

页数：2

共 50 条

[1] ORAL LPCN 1148 IMPROVES SARCOPENIA AND HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS
Bruno, Benjamin J.
Weavil, Joshua C.
Ogle, Jonathan
Chidambaram, Nachiappan
Carey, Elizabeth J.
Danford, Christopher J.
Fricker, Zachary P.
Galati, Joseph S.
Lee, William M.
Mantry, Parvez S.
Shetty, Kirti
DelConte, Anthony, III
Patel, Mahesh V.
Lai, Jennifer C.
Sanyal, Arun J.
HEPATOLOGY, 2024, 79 (02) : E35 - E36
[2] Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis: A randomized, placebo-controlled phase 2 trial
Bruno, Benjamin J.
Weavil, Joshua C.
Ogle, Jonathan
Chidambaram, Nachiappan
Carey, Elizabeth J.
Danford, Christopher J.
Fricker, Zachary P.
Galati, Joseph S.
Lee, William M.
Mantry, Parvez S.
Shetty, Kirti
Delconte, Anthony
Patel, Mahesh V.
Lai, Jennifer C.
Sanyal, Arun J.
HEPATOLOGY, 2025,
[3] A 52-WEEK PHASE 3 CLINICAL TRIAL OF RESMETIROM IN 180 PATIENTS WITH WELL-COMPENSATED NASH CIRRHOSIS
Harrison, Stephen A.
Alkhouri, Naim
Taub, Rebecca A.
Neff, Guy W.
Kowdley, Kris V.
Noureddin, Mazen
HEPATOLOGY, 2022, 76 : S90 - S92
[4] Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis
Kavanaugh, Arthur
Mease, Philip J.
Gomez-Reino, Juan J.
Adebajo, Adewale O.
Wollenhaupt, Juergen
Gladman, Dafna D.
Hochfeld, Marla
Teng, Lichen L.
Schett, Georg
Lespessailles, Eric
Hall, Stephen
JOURNAL OF RHEUMATOLOGY, 2015, 42 (03) : 479 - 488
[5] Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Mease, Philip J.
Deodhar, Atul
van der Heijde, Desiree
Behrens, Frank
Kivitz, Alan
Neal, Jeffrey
Nys, Marleen
Lehman, Tom
Delev, Nikolay
Korish, Shimon
Nowak, Miroslawa
Banerjee, Subhashis
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3167 - 3168
[6] Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes
Pozzilli, Paolo
Bosi, Emanuele
Cirkel, Deborah
Harris, Julia
Leech, Nicola
Tinahones, Francisco J.
Vantyghem, Marie-Christine
Vlasakakis, Georgios
Ziegler, Anette-Gabriele
Janmohamed, Salim
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (06): : E2192 - E2206
[7] Nutritional therapy improves minimal hepatic encephalopathy in cirrhosis by improvement in sarcopenia, proinflammatory cytokines and myostatin: a double blind randomized controlled trial
Maharshi, Sudhir
Sharma, Barjesh
Sachdeva, Sanjeev
Mahajan, Bhawna
Sharma, Ashok
Bara, Sushma
Srivastava, Siddharth
Kumar, Ajay
Dalal, Ashok
Sonika, Ujjwal
JOURNAL OF HEPATOLOGY, 2023, 78 : S235 - S235
[8] Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis (PALACE 2)
Cutolo, Maurizio
Myerson, Gary E.
Fleischmann, Roy M.
Liote, Frederic
Diaz-Gonzalez, Federico
Van den Bosch, Filip
Marzo-Ortega, Helena
Feist, Eugen
Shah, Kamal
Hu, ChiaChi
Stevens, Randall M.
Poder, Airi
ARTHRITIS AND RHEUMATISM, 2013, 65 : S346 - S347
[9] LONG-TERM (52-WEEK) RESULTS OF A PHASE 3, RANDOMIZED, CONTROLLED TRIAL OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS
Kavanaugh, A.
Mease, P. J.
Adebajo, A. O.
Wollenhaupt, J.
Hu, C.
Shah, K.
Stevens, R. M.
Gomez-Reino, J. J.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 163 - 163
[10] ORAL ZINC SUPPLEMENTATION IMPROVES CHRONIC HEPATIC-ENCEPHALOPATHY - RESULTS OF A RANDOMIZED CONTROLLED CLINICAL-TRIAL
REDING, P
DUCHATEAU, J
BATAILLE, C
HEPATOLOGY, 1984, 4 (04) : 766 - 766

← 1 2 3 4 5 →